\n<\/p>\n
Breast cancer is one of the most common cancers in the United States, accounting for As GLP-1 medications<\/a> become a widespread option for the treatment of obesity and type 2 diabetes, a recent study examined their effects on breast cancer outcomes. <\/p>\n<\/div>\n The findings, published in \u201c[Breast cancer] patients with obesity or pre-existing type 2 diabetes often face more complex breast cancer journeys,\u201d said lead study author Kristina L. Tatum<\/a>, PsyD, MS, <\/span>an instructor in the Department of Social and Behavioral Sciences at the School of Public Health at Virginia Commonwealth University.<\/p>\n<\/div>\n \u201cOur findings are encouraging because they suggest that GLP-1RA use may be associated with improved survival and lower recurrence among these patients<\/span>,\u201d Tatum told Healthline. <\/p>\n<\/div>\n \u201cWhile causation cannot be confirmed from this observational study, the findings provide important data for clinicians and patients with obesity and\/or type 2 diabetes to consider as we continue to learn more about the possibilities of GLP-1RA therapies in breast cancer survivorship,\u201d she said.<\/p>\n<\/div>\n<\/div>\n With around 1 in 8 U.S. adults<\/a> having used a GLP-1, like Ozempic<\/a>, Wegovy<\/a>, and Mounjaro<\/a>, at some point, including 40% with diabetes and 25% with heart disease, the broader health implications of this class of drugs are of increasing interest to researchers. <\/p>\n<\/div>\n While the effects of GLP-1 drugs on breast cancer<\/a> warrant further investigation, the relationship between obesity and cancer may play a role. <\/p>\n<\/div>\n GLP-1 medications, which are highly effective for weight loss, could therefore help lower these risks, as the new study suggests.<\/p>\n<\/div>\n